A large population-based cohort study demonstrated a slightly increased risk of anxiety, depression, and suicidal behavior in people treated with GLP-1 receptor agonists, particularly among younger patients with obesity but without diabetes [59]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.